Versican G3 domain modulates breast cancer cell apoptosis: A mechanism for breast cancer cell response to chemotherapy and egfr therapy

PLoS ONE

Volumn 6, Issue 11, 2011, Pages

  Du, William Weidong ^a,b   Yang, Burton B ^b,c   Yang, Bing L ^a,b   Deng, Zhaoqun ^b,c   Fang, Ling ^b,c   Shan, Sze Wan ^b,c   Jeyapalan, Zina ^b,c   Zhang, Yaou ^d   Seth, Arun ^b,c   Yee, Albert J ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b Canada   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d TSINGHUA UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; CERAMIDE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIRUBICIN; GLYCOGEN SYNTHASE KINASE 3BETA; MITOGEN ACTIVATED PROTEIN KINASE; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE; TRASTUZUMAB; UNCLASSIFIED DRUG; VERSICAN; VERSICAN G3; ANTHRA(1,9 CD)PYRAZOL 6(2H) ONE; ANTHRA(1,9-CD)PYRAZOL-6(2H)-ONE; ANTHRACENE DERIVATIVE; DRUG DERIVATIVE; ENHANCED GREEN FLUORESCENT PROTEIN; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; GREEN FLUORESCENT PROTEIN; N ACETYLSPHINGOSINE; N-ACETYLSPHINGOSINE; QUINAZOLINE DERIVATIVE; SPHINGOSINE; TAXOID; TYRPHOSTIN;

3' UNTRANSLATED REGION; ANIMAL CELL; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CELL VIABILITY; CONTROLLED STUDY; CULTURE MEDIUM; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PROTEIN DOMAIN; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; BREAST TUMOR; CELL CYCLE; CELL SURVIVAL; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; GENETICS; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

BOVINAE;

ANIMALS; ANTHRACENES; APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL CYCLE; CELL SURVIVAL; DOXORUBICIN; EPIRUBICIN; FEMALE; GLYCOGEN SYNTHASE KINASE 3; GREEN FLUORESCENT PROTEINS; HUMANS; MICE; QUINAZOLINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SPHINGOSINE; TAXOIDS; TYRPHOSTINS; VERSICANS;

EID: 80655141543     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0026396     Document Type: Article

References (72)

1. Pusztai L, Esteva FJ, Cristofanilli M, Hung MC, Hortobagyi GN, (1999) Chemo-signal therapy, an emerging new approach to modify drug resistance in breast cancer. Cancer Treat Rev 25: 271-277.
2. Flowers M, Thompson PA, (2009) t10c12 conjugated linoleic acid suppresses HER2 protein and enhances apoptosis in SKBr3 breast cancer cells: possible role of COX2. PLoS One 4: e5342.
3. Xu J, Zhou JY, Wei WZ, Wu GS, (2010) Activation of the Akt survival pathway contributes to TRAIL resistance in cancer cells. PLoS One 5: e10226.
4. Boldt S, Weidle UH, Kolch W, (2002) The role of MAPK pathways in the action of chemotherapeutic drugs. Carcinogenesis 23: 1831-1838.
5. Cattaruzza S, Schiappacassi M, Kimata K, Colombatti A, Perris R, (2004) The globular domains of PG-M/versican modulate the proliferation-apoptosis equilibrium and invasive capabilities of tumor cells. Faseb J 18: 779-781.
6. Kaufmann SH, (1998) Cell death induced by topoisomerase-targeted drugs: more questions than answers. Biochim Biophys Acta 1400: 195-211.
7. LaPierre DP, Lee DY, Li SZ, Xie YZ, Zhong L, et al. (2007) The ability of versican to simultaneously cause apoptotic resistance and sensitivity. Cancer Res 67: 4742-4750.
8. Wu Y, Wu J, Lee DY, Yee A, Cao L, et al. (2005) Versican protects cells from oxidative stress-induced apoptosis. Matrix Biol 24: 3-13.
9. Yamaguchi Y, (2000) Lecticans: organizers of the brain extracellular matrix. Cell Mol Life Sci 57: 276-289.
10. Zimmermann DR, Ruoslahti E, (1989) Multiple domains of the large fibroblast proteoglycan, versican. Embo J 8: 2975-2981.
11. Zheng PS, Wen J, Ang LC, Sheng W, Viloria-Petit A, et al. (2004) Versican/PG-M G3 domain promotes tumor growth and angiogenesis. Faseb J 18: 754-756.
12. Wu YJ, La Pierre DP, Wu J, Yee AJ, Yang BB, (2005) The interaction of versican with its binding partners. Cell Res 15: 483-494.
13. Zheng PS, Vais D, Lapierre D, Liang YY, Lee V, et al. (2004) PG-M/versican binds to P-selectin glycoprotein ligand-1 and mediates leukocyte aggregation. J Cell Sci 117: 5887-5895.
14. Jeffs AR, Glover AC, Slobbe LJ, Wang L, He S, et al. (2009) A gene expression signature of invasive potential in metastatic melanoma cells. PLoS One 4: e8461.
15. Nara Y, Kato Y, Torii Y, Tsuji Y, Nakagaki S, et al. (1997) Immunohistochemical localization of extracellular matrix components in human breast tumours with special reference to PG-M/versican. Histochem J 29: 21-30.
16. Ricciardelli C, Brooks JH, Suwiwat S, Sakko AJ, Mayne K, et al. (2002) Regulation of stromal versican expression by breast cancer cells and importance to relapse-free survival in patients with node-negative primary breast cancer. Clin Cancer Res 8: 1054-1060.
17. Ricciardelli C, Mayne K, Sykes PJ, Raymond WA, McCaul K, et al. (1998) Elevated levels of versican but not decorin predict disease progression in early-stage prostate cancer. Clin Cancer Res 4: 963-971.
18. Suwiwat S, Ricciardelli C, Tammi R, Tammi M, Auvinen P, et al. (2004) Expression of extracellular matrix components versican, chondroitin sulfate, tenascin, and hyaluronan, and their association with disease outcome in node-negative breast cancer. Clin Cancer Res 10: 2491-2498.
19. Yee AJ, Akens M, Yang BL, Finkelstein J, Zheng PS, et al. (2007) The effect of versican G3 domain on local breast cancer invasiveness and bony metastasis. Breast Cancer Res 9: R47.
20. Du WW, Yang BB, Shatseva TA, Yang BL, Deng Z, et al. (2010) Versican G3 Promotes Mouse Mammary Tumor Cell Growth, Migration, and Metastasis by Influencing EGF Receptor Signaling. PLoS ONE 5 (11): e13828 doi:10.1371/journal.pone.0013828.
21. Kong A, Calleja V, Leboucher P, Harris A, Parker PJ, et al. (2008) HER2 oncogenic function escapes EGFR tyrosine kinase inhibitors via activation of alternative HER receptors in breast cancer cells. PLoS One 3: e2881.
22. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, et al. (2007) Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 1773: 1263-1284.
23. Johnston JB, Navaratnam S, Pitz MW, Maniate JM, Wiechec E, et al. (2006) Targeting the EGFR pathway for cancer therapy. Curr Med Chem 13: 3483-3492.
24. Nitta M, Kozono D, Kennedy R, Stommel J, Ng K, et al. (2010) Targeting EGFR induced oxidative stress by PARP1 inhibition in glioblastoma therapy. PLoS One 5: e10767.
25. Dykxhoorn DM, Wu Y, Xie H, Yu F, Lal A, et al. (2009) miR-200 enhances mouse breast cancer cell colonization to form distant metastases. PLoS One 4: e7181.
26. Aslakson CJ, Miller FR, (1992) Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 52: 1399-1405.
27. Walker-Nasir E, Codington JF, Jahnke MR, Fuller TC, Jeanloz RW, (1982) Isolation and partial characterization of surface components of cell line MDA-MB-231 derived from a human metastatic breast carcinoma. J Natl Cancer Inst 69: 371-380.
28. Hambly RJ, Double JA, Thompson MJ, Bibby MC, (1997) Establishment and characterisation of new cell lines from human breast tumours initially established as tumour xenografts in NMRI nude mice. Breast Cancer Res Treat 43: 247-258.
29. Horwitz KB, Costlow ME, McGuire WL, (1975) MCF-7; a human breast cancer cell line with estrogen, androgen, progesterone, and glucocorticoid receptors. Steroids 26: 785-795.
30. Buick RN, Filmus J, Church J, (1990) Studies of EGF-mediated growth control and signal transduction using the MDA-MB-468 human breast cancer cell line. Prog Clin Biol Res 354A: 179-191.
31. Zhang Y, Cao L, Yang BL, Yang BB, (1998) The G3 domain of versican enhances cell proliferation via epidermial growth factor-like motifs. J Biol Chem 273: 21342-21351.
32. Wu Y, Zhang Y, Cao L, Chen L, Lee V, et al. (2001) Identification of the motif in versican G3 domain that plays a dominant-negative effect on astrocytoma cell proliferation through inhibiting versican secretion and binding. J Biol Chem 276: 14178-14186.
33. Yang BL, Cao L, Kiani C, Lee V, Zhang Y, et al. (2000) Tandem repeats are involved in G1 domain inhibition of versican expression and secretion and the G3 domain enhances glycosaminoglycan modification and product secretion via the complement-binding protein-like motif. J Biol Chem 275: 21255-21261.
34. Chen L, Wu Y, Lee V, Kiani C, Adams ME, et al. (2002) The folded modules of aggrecan G3 domain exert two separable functions in glycosaminoglycan modification and product secretion. J Biol Chem 277: 2657-2665.
35. Kiani C, Lee V, Cao L, Chen L, Wu Y, et al. (2001) Roles of aggrecan domains in biosynthesis, modification by glycosaminoglycans and product secretion. Biochem J 354: 199-207.
36. Kahai S, Lee SC, Lee DY, Yang J, Li M, et al. (2009) MicroRNA miR-378 regulates nephronectin expression modulating osteoblast differentiation by targeting GalNT-7. PLoS One 4: e7535.
37. Shan SW, Lee DY, Deng Z, Shatseva T, Jeyapalan Z, et al. (2009) MicroRNA MiR-17 retards tissue growth and represses fibronectin expression. Nat Cell Biol 11: 1031-1038.
38. Wang CH, Lee DY, Deng Z, Jeyapalan Z, Lee SC, et al. (2008) MicroRNA miR-328 regulates zonation morphogenesis by targeting CD44 expression. PLoS One 3: e2420.
39. Lee DY, Deng Z, Wang CH, Yang BB, (2007) MicroRNA-378 promotes cell survival, tumor growth, and angiogenesis by targeting SuFu and Fus-1 expression. Proc Natl Acad Sci U S A 104: 20350-20355.
40. Lyseng-Williamson KA, Fenton C, (2005) Docetaxel: a review of its use in metastatic breast cancer. Drugs 65: 2513-2531.
41. Clarke SJ, Rivory LP, (1999) Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet 36: 99-114.
42. Schabel FM Jr, (1977) Rationale for adjuvant chemotherapy. Cancer 39: 2875-2882.
43. Brock N, (1996) The history of the oxazaphosphorine cytostatics. Cancer 78: 542-547.
44. Schaller G, Bangemann N, Becker C, Buhler H, Opri F, et al. (1999) Therapy of metastatic breast cancer with humanized antibodies against the HER2 receptor protein. J Cancer Res Clin Oncol 125: 520-524.
45. Filmus J, Pollak MN, Cailleau R, Buick RN, (1985) MDA-468, a human breast cancer cell line with a high number of epidermal growth factor (EGF) receptors, has an amplified EGF receptor gene and is growth inhibited by EGF. Biochem Biophys Res Commun 128: 898-905.
46. Wu Y, Chen L, Cao L, Sheng W, Yang BB, (2004) Overexpression of the C-terminal PG-M/versican domain impairs growth of tumor cells by intervening in the interaction between epidermal growth factor receptor and beta1-integrin. J Cell Sci 117: 2227-2237.
47. Sheng W, Wang G, La Pierre DP, Wen J, Deng Z, et al. (2006) Versican mediates mesenchymal-epithelial transition. Mol Biol Cell 17: 2009-2020.
48. Lee DY, Shatseva T, Jeyapalan Z, Du WW, Deng Z, et al. (2009) A 3′-untranslated region (3′UTR) induces organ adhesion by regulating miR-199a* functions. PLoS One 4: e4527.
49. Mendelsohn J, Baselga J, (2000) The EGF receptor family as targets for cancer therapy. Oncogene 19: 6550-6565.
50. Prenzel N, Zwick E, Leserer M, Ullrich A, (2000) Tyrosine kinase signalling in breast cancer. Epidermal growth factor receptor: convergence point for signal integration and diversification. Breast Cancer Res 2: 184-190.
51. Brown LF, Guidi AJ, Schnitt SJ, Van De Water L, Iruela-Arispe ML, et al. (1999) Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast. Clin Cancer Res 5: 1041-1056.
52. Sebolt-Leopold JS, Herrera R, (2004) Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 4: 937-947.
53. Kim HP, Yoon YK, Kim JW, Han SW, Hur HS, et al. (2009) Lapatinib, a dual EGFR and HER2 tyrosine kinase inhibitor, downregulates thymidylate synthase by inhibiting the nuclear translocation of EGFR and HER2. PLoS One 4: e5933.
54. Roberts PJ, Der CJ, (2007) Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26: 3291-3310.
55. Nahta R, Hortobagyi GN, Esteva FJ, (2003) Growth factor receptors in breast cancer: potential for therapeutic intervention. Oncologist 8: 5-17.
56. Gu L, Waliany S, Kane SE, (2009) Darpp-32 and its truncated variant t-Darpp have antagonistic effects on breast cancer cell growth and herceptin resistance. PLoS One 4: e6220.
57. Arteaga C, (2003) Targeting HER1/EGFR: a molecular approach to cancer therapy. Semin Oncol 30: 3-14.
58. Graham DL, Hillman DW, Hobday TJ, Rousey SR, Nair SG, et al. (2005) Phase II study of erlotinib (OSI-774) plus gemcitabine as first-or second-line therapy for metastatic breast cancer (MBC); 2005. Abstract No: 644.
59. Polychronis ASH, Hadjiminas D, Singhal H, Mansi JL, Ali S, et al. (2005) Antiproliferative and molecular effects of neoadjuvant (pre-operative) gefitinib alone or in combination with anastrozole in epidermal growth factor receptor (EGFR) positive, estrogen receptor alpha (ERa) positive patients with primary breast cancer; 2005. Abstract No: 552.
60. Ciardiello FTT, Caputo F, de Laurentiis M, Tortora G, Palmieri G, de Vita F, et al. (2005) Phase II trial of gefitinib combined with docetaxel as first-line therapy in patients with metastatic breast cancer; 2005. Abstract No: 3080.
61. Arteaga CL, Baselga J, (2004) Tyrosine kinase inhibitors: why does the current process of clinical development not apply to them? Cancer Cell 5: 525-531.
62. Theocharis AD, Skandalis SS, Tzanakakis GN, Karamanos NK, (2010) Proteoglycans in health and disease: novel roles for proteoglycans in malignancy and their pharmacological targeting. Febs J 277: 3904-3923.
63. Shimizu-Hirota R, Sasamura H, Mifune M, Nakaya H, Kuroda M, et al. (2001) Regulation of vascular proteoglycan synthesis by angiotensin II type 1 and type 2 receptors. J Am Soc Nephrol 12: 2609-2615.
64. Syrokou A, Tzanakakis GN, Hjerpe A, Karamanos NK, (1999) Proteoglycans in human malignant mesothelioma. Stimulation of their synthesis induced by epidermal, insulin and platelet-derived growth factors involves receptors with tyrosine kinase activity. Biochimie 81: 733-744.
65. Wu Y, Chen L, Zheng PS, Yang BB, (2002) beta 1-Integrin-mediated glioma cell adhesion and free radical-induced apoptosis are regulated by binding to a C-terminal domain of PG-M/versican. J Biol Chem 277: 12294-12301.
66. Aguirre-Ghiso JA, Liu D, Mignatti A, Kovalski K, Ossowski L, (2001) Urokinase receptor and fibronectin regulate the ERK(MAPK) to p38(MAPK) activity ratios that determine carcinoma cell proliferation or dormancy in vivo. Mol Biol Cell 12: 863-879.
67. Frame S, Cohen P, (2001) GSK3 takes centre stage more than 20 years after its discovery. Biochem J 359: 1-16.
68. Jamerson MH, Johnson MD, Dickson RB, (2000) Dual regulation of proliferation and apoptosis: c-myc in bitransgenic murine mammary tumor models. Oncogene 19: 1065-1071.
69. Marshall CJ, (1995) Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 80: 179-185.
70. Recchia I, Rucci N, Funari A, Migliaccio S, Taranta A, et al. (2004) Reduction of c-Src activity by substituted 5,7-diphenyl-pyrrolo[2,3-d]-pyrimidines induces osteoclast apoptosis in vivo and in vitro. Involvement of ERK1/2 pathway. Bone 34: 65-79.
71. Navolanic PM, Steelman LS, McCubrey JA, (2003) EGFR family signaling and its association with breast cancer development and resistance to chemotherapy (Review). Int J Oncol 22: 237-252.
72. Langlois B, Perrot G, Schneider C, Henriet P, Emonard H, et al. (2010) LRP-1 promotes cancer cell invasion by supporting ERK and inhibiting JNK signaling pathways. PLoS One 5: e11584.